Endovascular Treatment of Cerebrovascular Diseases Guided by Optical Coherence Tomography (OCT) Technology(CVD-OCT)
NCT ID: NCT06986330
Last Updated: 2025-06-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
200 participants
OBSERVATIONAL
2023-11-30
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In summary, OCT can accurately assess the nature of cerebrovascular lesions and plaques and guide clinical interventions.For medical centers that have the conditions, it is recommended to standardize the application of OCT to guide the interventional precision treatment of ischemic cerebrovascular disease.In the future, a clinical study database of OCT in Chinese patients with ischemic cerebrovascular disease should be established to provide evidence-based medical evidence of OCT in the diagnosis and treatment
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fundus Optical coheRence Tomography Angiography Evaluation for Small-vessel Health in Cerebral Small Vessel Disease
NCT06431711
Investigating the Retardation Effect of OCTA-Guided Targeted Photocoagulation on the Progression of Non-Perfusion Areas in Diabetic Retinopathy Patients
NCT06821633
Optical Coherence Tomography in Retinal Vein Occlusion
NCT06886893
Optical Coherence Tomography Angiography Evaluation of Ocular Changes in Patients With Carotid Artery Stenosis
NCT04326842
Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.
NCT03903965
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1.1 Ischemic stroke and atherosclerosis
Stroke is divided into ischemic stroke and hemorrhagic stroke, of which ischemic stroke accounts for 80%. The etiology of ischemic stroke can be divided into aortic atherosclerosis type (Large-at) according to the trial of Org 10172 in Acute Stroke Treatment (TOAST) Ery atherosclerosis, LAA), cardiogenic embolism type, small arterial occlusion type, other causal type and unexplained type 5 types 3. LAA-type ischemic stroke refers to the stenosis or occlusion of more than 50% of the main trunk or cortical branches of the cerebrovascular caused by atherosclerosis, resulting in the symptoms of the corresponding blood supply area. A number of studies based on Chinese hospital data show that the proportion of LAA ischemic stroke varies from region to region, ranging from 11.4% to 67.6% 4. On the surface of the study, about 30%-50% of ischemic stroke can be attributed to intracranial atherosclerotic stenosis, and about 8%-10% of ischemic stroke can be attributed to carotid atherosclerosis.
The occurrence, development and complications of atherosclerosis is a slow process. It is a chronic inflammatory reaction of vascular endothelial cell dysfunction combined with macrophages, smooth muscle cells and low-density lipoprotein cholesterol, as well as a variety of inflammatory factors, which can lead to endovascular lipid deposition and fibrous proliferation. , calcium sedimentation, cholesterol crystallization, plaque erosion, plaque rupture, thrombosis; medium membrane thinning, fiber proliferation; a series of slow-progressing pathophysiological processes with narrowing and even occlusion of the lumen 6. As a common cause of ischemic stroke, the pathophysiological mechanism of ischemic stroke is divided into 2 categories: 1 The formation of atherosclerotic plaques of large blood vessels inside and outside the skull leads to severe narrowing or even occlusion of the lumen, resulting in reduced perfusion of brain tissue and ischemic infarction; 2 The thrombus on the surface of large vascular plaques can be shed with blood flow. It causes distal vascular embolism, causing ischemic infarction of brain tissue in the corresponding blood supply area.
1.2 Diagnosis and treatment strategies and dilemmas of cerebral vascular atherosclerotic stenosis
At present, the treatment of patients with cerebral vascular atherosclerotic stenosis mainly includes drug treatment and surgical treatment or intravascular intervention treatment. Drug treatment includes anti-platelet aggregation treatment and lipid regulation and plaque stabilization treatment. In addition, it also includes treatments such as risk factor control.
Surgical treatment or intravascular treatment: A number of randomized controlled studies have shown that symptomatic carotid artery patients with stenosis degree of ≥50% diagnosed by transcerebrovascular digital subtraction angiography (DSA) and patients with asymptomatic carotid stenosis with stenosis degree of ≥70%, carotid endatrial stripping or carotid branch can be adopted. Frame implantation is used to reduce the risk of stroke or recurrence. 9,10 For patients with unfavorable anatomical structure of the neck, stenosis after carotid inner membrane peeling, accompanied by perioperative risk, previous radiotherapy history or other patients who can increase the risk of endometrial stripping, less invasive carotid stent implantation can be used for treatment.
The evidence-based evidence is still insufficient for the superiority and inferiority of the efficacy of intravascular interventional treatment in patients with intracranial artery stenosis and the efficacy of the best drug treatment. Current studies show that intravascular interventional treatment has failed to reduce the risk of stroke recurrence in patients with symptomatic intracranial atherosclerotic stenosis compared with simple drug treatment, which may be related to the screening of patients. Previous randomized controlled trials screened patients only based on the degree of stenosis of the vascular lumen, ignoring the impact of plaque characteristics on the risk of stroke. More and more evidence shows that the risk of stroke is closely related to plaque vulnerability.
Although DSA is currently the gold standard for the diagnosis of cerebral vascular stenosis, DSA cannot recognize plaque characteristics. In recent years, with the development of vascular wall imaging technology, more and more research on plaque susceptibility and stroke risk have become more and more profound. These studies may change the treatment strategy of patients with cerebral atherosclerosis.
1.3 Application of optical coherence tomography (OCT) technology in cerebral vascular atherosclerotic stenosis
OCT technology is used in the evaluation of intracranial and extracranial lesions. ( 1) Preoperative evaluation: The morphological characteristics of carotid atherosclerotic plaques can be evaluated through OCT before operation, so as to identify vulnerable plaques and guide interventional treatment. Studies have shown that through the plaque image characteristics observed by OCT and based on the "thin fiber cap" characteristics of the plaque, the rupture of atherosclerotic plaque and the risk of thrombosis can be predicted, and symptomatic carotid plaques can be identified. Similarly, the research results based on the characteristics of OCT plaque show that there is a certain correlation between the characteristics of OCT plaque and the degree of carotid artery stenosis and ischemic symptoms. Therefore, it is important to use OCT to evaluate the characteristics of plaques before cerebrovascular interventional treatment, identify high-risk plaques that are prone to ischemia events, and guide carotid interventional treatment, especially for lesions where the degree of vascular stenosis does not reach the level of intervention, but there are susceptible plaques. ( 2) Evaluation of the immediate effect after interventional treatment: At present, OCT has been used to evaluate the immediate expansion rate of the relevant stent after stent placement, stent wall adhession, the protrusion of lesion tissue into the vascular cavity and thrombosis in the stent, etc. In addition, in intracranial vascular acute occlusion and re-permission surgery, the application of OCT can identify the nature of lesions in the treatment process, such as dissection, atherosclerotic stenosis and other lesions, and guide the formulation of surgical strategies. ( 3) Interventional treatment follow-up: OCT can be used for follow-up after interventional treatment to understand the repair of the inner membrane after stent, stent re-stenosis, neonatal atherosclerosis and thrombosis, etc.
In summary, OCT can accurately evaluate the nature of cerebrovascular lesions and plaques, and guide clinical interventional diagnosis and treatment. For qualified medical centers, it is recommended to apply OCT in a standardized way to guide the interventional and accurate treatment of ischemic cerebrovascular disease. In the future, an OCT clinical research database for patients with ischemic cerebrovascular disease in China should be established to provide evidence-based medical evidence of OCT in the diagnosis and treatment of cerebrovascular disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
oct
The diagnosis and treatment behavior of all subjects in this study followed the requirements of the current guidelines, and there were no additional interventions.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Cerebral angiography or intervention with OCT is required in the course of clinical diagnosis and treatment;
3. Informed consent signed by the patient or the patient's legally authorized representative.
Exclusion Criteria
2. Patients with tortuous blood vessels who are unable to complete OCT.
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Wannan Medical College
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20231130
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.